Rani Therapeutics Holdings (RANI) Income from Non-Controlling Interests (2020 - 2026)

Rani Therapeutics Holdings' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at -$982000.0 for Q1 2026.

• In Q1 2026, Income from Non-Controlling Interests rose 82.06% year-over-year to -$982000.0; the TTM figure through Mar 2026 stood at -$6.8 million (up 72.58% YoY), while the FY2025 annual figure was -$11.3 million, up 57.55% from the prior year.
• Income from Non-Controlling Interests for Q1 2026 stood at -$982000.0, down from $1.2 million in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $1.2 million in Q4 2025, with the low at -$9.4 million in Q2 2023.
• The 5-year median for Income from Non-Controlling Interests is -$7.0 million (2023), against an average of -$6.2 million.
• The sharpest annual moves came in 2022 and 2025: Income from Non-Controlling Interests plunged 52.09% in 2022, then jumped 118.17% in 2025.
• Rani Therapeutics Holdings' Income from Non-Controlling Interests stood at -$8.6 million in 2022, then climbed by 18.69% to -$7.0 million in 2023, then rose by 2.62% to -$6.8 million in 2024, then surged by 118.17% to $1.2 million in 2025, then sank by 179.77% to -$982000.0 in 2026.
• Business Quant data shows RANI's Income from Non-Controlling Interests at -$982000.0 in Q1 2026, $1.2 million in Q4 2025, and -$2.5 million in Q3 2025.